The incidences of adverse events were similar in the simeprevir and placebo groups at @ weeks ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) and for the entire treatment ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) , irrespective of the peginterferon alfa used .